Provexis plc (PXS) - Net Assets
Based on the latest financial reports, Provexis plc (PXS) has net assets worth GBX610.89K GBX (≈ $74.33 USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX841.84K ≈ $102.43 USD) and total liabilities (GBX230.95K ≈ $28.10 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Provexis plc's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX610.89K |
| % of Total Assets | 72.57% |
| Annual Growth Rate | 9.76% |
| 5-Year Change | -33.13% |
| 10-Year Change | 434.74% |
| Growth Volatility | 433.39 |
Provexis plc - Net Assets Trend (2004–2025)
This chart illustrates how Provexis plc's net assets have evolved over time, based on quarterly financial data. Check PXS tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Provexis plc (2004–2025)
The table below shows the annual net assets of Provexis plc from 2004 to 2025. For live valuation and market cap data, see Provexis plc (PXS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | GBX763.82K ≈ $92.93 |
+300.77% |
| 2024-03-31 | GBX190.59K ≈ $23.19 |
-71.02% |
| 2023-03-31 | GBX657.65K ≈ $80.02 |
-32.14% |
| 2022-03-31 | GBX969.08K ≈ $117.91 |
-15.16% |
| 2021-03-31 | GBX1.14 Million ≈ $138.97 |
+258.41% |
| 2020-03-31 | GBX318.68K ≈ $38.77 |
-5.96% |
| 2019-03-31 | GBX338.89K ≈ $41.23 |
+2.92% |
| 2018-03-31 | GBX329.26K ≈ $40.06 |
+1223.07% |
| 2017-03-31 | GBX24.89K ≈ $3.03 |
-82.58% |
| 2016-03-31 | GBX142.84K ≈ $17.38 |
-41.91% |
| 2015-03-31 | GBX245.90K ≈ $29.92 |
-54.04% |
| 2014-03-31 | GBX535.08K ≈ $65.10 |
-93.23% |
| 2013-03-31 | GBX7.91 Million ≈ $961.92 |
-30.03% |
| 2012-03-31 | GBX11.30 Million ≈ $1.37K |
-1.59% |
| 2011-03-31 | GBX11.48 Million ≈ $1.40K |
+3.79% |
| 2010-03-31 | GBX11.06 Million ≈ $1.35K |
+99.96% |
| 2009-03-31 | GBX5.53 Million ≈ $673.08 |
-27.07% |
| 2008-03-31 | GBX7.58 Million ≈ $922.88 |
+14.77% |
| 2007-03-31 | GBX6.61 Million ≈ $804.12 |
-25.32% |
| 2006-03-31 | GBX8.85 Million ≈ $1.08K |
+1635.29% |
| 2005-03-31 | GBX510.00K ≈ $62.05 |
+372.22% |
| 2004-03-31 | GBX108.00K ≈ $13.14 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Provexis plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1954520900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX2.35 Million | 180.79% |
| Other Components | GBX19.43 Million | 1497.64% |
| Total Equity | GBX1.30 Million | 100.00% |
Provexis plc Competitors by Market Cap
The table below lists competitors of Provexis plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mitra Komunikasi Nusantara Tbk PT
JK:MKNT
|
$322.28K |
|
Sanco Industries Limited
NSE:SANCO
|
$322.53K |
|
Dewhurst plc
LSE:DWHA
|
$323.07K |
|
Subsea 7 SA
LSE:0OGK
|
$324.38K |
|
Abingdon Health Plc
LSE:ABDX
|
$320.76K |
|
Kavango Resources PLC
LSE:KAV
|
$320.59K |
|
Desarrolladora Homex S.A.B. de C.V
MX:HOMEX
|
$320.51K |
|
GO.D.M Investments Ltd
TA:GODM
|
$319.94K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Provexis plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 724,337 to 1,297,564, a change of 573,227 (79.1%).
- Net loss of 452,720 reduced equity.
- New share issuances of 857,630 increased equity.
- Other comprehensive income decreased equity by 6,599,174.
- Other factors increased equity by 6,767,491.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-452.72K | -34.89% |
| Share Issuances | GBX857.63K | +66.1% |
| Other Comprehensive Income | GBX-6.60 Million | -508.58% |
| Other Changes | GBX6.77 Million | +521.55% |
| Total Change | GBX- | 79.14% |
Book Value vs Market Value Analysis
This analysis compares Provexis plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1980.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 279.38x to 1980.57x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | GBX0.00 | GBX1.13 | x |
| 2005-03-31 | GBX0.02 | GBX1.13 | x |
| 2006-03-31 | GBX0.04 | GBX1.13 | x |
| 2007-03-31 | GBX0.03 | GBX1.13 | x |
| 2008-03-31 | GBX0.02 | GBX1.13 | x |
| 2009-03-31 | GBX0.01 | GBX1.13 | x |
| 2010-03-31 | GBX0.01 | GBX1.13 | x |
| 2011-03-31 | GBX0.01 | GBX1.13 | x |
| 2012-03-31 | GBX0.01 | GBX1.13 | x |
| 2013-03-31 | GBX0.01 | GBX1.13 | x |
| 2014-03-31 | GBX0.00 | GBX1.13 | x |
| 2015-03-31 | GBX0.00 | GBX1.13 | x |
| 2016-03-31 | GBX0.00 | GBX1.13 | x |
| 2017-03-31 | GBX0.00 | GBX1.13 | x |
| 2018-03-31 | GBX0.00 | GBX1.13 | x |
| 2019-03-31 | GBX0.00 | GBX1.13 | x |
| 2020-03-31 | GBX0.00 | GBX1.13 | x |
| 2021-03-31 | GBX0.00 | GBX1.13 | x |
| 2022-03-31 | GBX0.00 | GBX1.13 | x |
| 2023-03-31 | GBX0.00 | GBX1.13 | x |
| 2024-03-31 | GBX0.00 | GBX1.13 | x |
| 2025-03-31 | GBX0.00 | GBX1.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Provexis plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -35.03%
- • Asset Turnover: 1.28x
- • Equity Multiplier: 0.78x
- Recent ROE (-34.89%) is above the historical average (-81.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -791.67% | -1140.00% | 0.23x | 2.99x | GBX-865.80K |
| 2005 | -214.12% | -352.26% | 0.21x | 2.85x | GBX-1.14 Million |
| 2006 | -0.55% | -18.28% | 0.03x | 1.09x | GBX-935.40K |
| 2007 | -36.74% | -3638.81% | 0.01x | 1.12x | GBX-3.10 Million |
| 2008 | -15.68% | -733.95% | 0.02x | 1.05x | GBX-1.95 Million |
| 2009 | -82.63% | -91420.00% | 0.00x | 1.04x | GBX-5.12 Million |
| 2010 | -14.90% | -10986.67% | 0.00x | 1.03x | GBX-2.75 Million |
| 2011 | -17.08% | -3968.00% | 0.00x | 1.04x | GBX-3.15 Million |
| 2012 | -33.63% | -111.36% | 0.26x | 1.16x | GBX-5.02 Million |
| 2013 | -53.05% | -78.04% | 0.54x | 1.27x | GBX-5.16 Million |
| 2014 | 56.88% | 12310.39% | 0.01x | 0.75x | GBX402.50K |
| 2015 | -70.09% | -1139.59% | 0.11x | 0.58x | GBX-497.75K |
| 2016 | -74.52% | -446.89% | 0.36x | 0.47x | GBX-464.53K |
| 2017 | -82.15% | -166.98% | 1.44x | 0.34x | GBX-426.35K |
| 2018 | -56.98% | -190.03% | 0.56x | 0.53x | GBX-526.74K |
| 2019 | -62.85% | -159.23% | 0.70x | 0.57x | GBX-594.67K |
| 2020 | -49.88% | -116.75% | 0.74x | 0.58x | GBX-487.67K |
| 2021 | -20.59% | -67.48% | 0.39x | 0.78x | GBX-506.63K |
| 2022 | -14.96% | -52.62% | 0.38x | 0.75x | GBX-374.16K |
| 2023 | -32.39% | -98.80% | 0.46x | 0.71x | GBX-504.19K |
| 2024 | -80.94% | -73.10% | 1.61x | 0.69x | GBX-658.68K |
| 2025 | -34.89% | -35.03% | 1.28x | 0.78x | GBX-582.48K |
Industry Comparison
This section compares Provexis plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,692,601,546
- Average return on equity (ROE) among peers: -8.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Provexis plc (PXS) | GBX610.89K | -791.67% | 0.38x | $321.11K |
| Allergy Therapeutics (AGY) | $14.59 Million | 5.64% | 0.90x | $3.74 Million |
| Animalcare Group Plc (ANCR) | $22.52 Million | 11.70% | 0.19x | $2.81 Million |
| Alliance Pharma plc (APH) | $70.78 Million | 11.85% | 0.52x | $4.26 Million |
| Celadon Pharmaceuticals PLC (CEL) | $6.41 Million | -74.61% | 0.03x | $112.25K |
| Chill Brands Group PLC (CHLL) | $7.01 Million | -48.07% | 0.05x | $133.61K |
| Eco Animal Health Group Plc (EAH) | $16.43 Million | -1.19% | 0.81x | $816.23K |
| HUTCHMED China Ltd (HCM) | $109.98 Million | -8.73% | 0.21x | $18.62 Million |
| Hikma Pharmaceuticals PLC (HIK) | $750.30 Million | 13.17% | 0.49x | $42.33 Million |
| Haleon PLC (HLN) | $26.22 Billion | 4.37% | 0.30x | $396.27 Million |
| Indivior PLC (INDV) | $-295.00 Million | 0.00% | 0.00x | $18.79 Million |
About Provexis plc
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and di… Read more